Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 23, 2026
IBM (IBM) Delivers Q2 2026 Earnings: +1% Revenue Growth with Software Momentum

IBM (IBM) Delivers Q2 2026 Earnings: +1% Revenue Growth with Software Momentum

Key Takeaways

  • IBM reported second-quarter 2026 revenue of $17.2 billion, up 1% year over year.
  • GAAP diluted earnings per share came in at $2.27, down 2% from the prior year.
  • Operating (non-GAAP) earnings per share rose 5% to $2.93.
  • Software revenue grew 5% to $7.8 billion, while Infrastructure revenue fell 7% to $3.8 billion.
  • The company updated full-year 2026 constant-currency revenue growth expectations to a range of 4% to 5%.
  • Free cash flow for the first half of the year was $4.8 billion, flat year over year.

Putting the Quarter in Context

IBM’s second-quarter results reflect ongoing shifts in its business mix as the company invests heavily in artificial intelligence capabilities. Software and consulting segments continue to drive the majority of revenue, while infrastructure faces cyclical pressures. The quarter’s performance provides investors with insight into IBM’s ability to execute on its AI strategy amid changing client spending patterns and macroeconomic conditions. Strong free cash flow generation and a consistent dividend also underscore the company’s financial discipline. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

What IBM Actually Reported

IBM reported total revenue of $17.2 billion for the second quarter of 2026, representing a 1% increase from the same period in 2025. GAAP diluted earnings per share from continuing operations were $2.27, down 2% year over year. Operating (non-GAAP) diluted earnings per share increased 5% to $2.93. Software revenue reached $7.8 billion, up 5%, driven by growth in hybrid cloud and data offerings. Consulting revenue was flat at $5.3 billion. Infrastructure revenue declined 7% to $3.8 billion, primarily due to lower IBM Z mainframe sales. The company generated $2.6 billion in net cash from operating activities and $2.5 billion in free cash flow during the quarter. IBM also declared a quarterly dividend of $1.69 per share. From what I see, the contrast between the software gains and infrastructure softness stands out clearly in these figures.

Market Reaction and Investor Sentiment

IBM shares experienced volatility following the earnings release, reflecting investor focus on the revenue miss relative to earlier expectations and the lowered full-year growth outlook. Analysts noted the contrast between solid software performance and weakness in infrastructure. The updated guidance signaled caution on near-term growth while emphasizing long-term AI investments. Market participants are closely watching how IBM’s go-to-market adjustments and productivity initiatives will influence future quarters.

Forward Outlook and Key Factors to Monitor

IBM lowered its full-year 2026 constant-currency revenue growth target to a range of 4% to 5%, citing revenue headwinds late in the second quarter. The company continues to expect free cash flow to increase by about $1 billion year over year and anticipates improved pre-tax income margin expansion.

Investors should monitor progress in high-growth software areas such as Red Hat, watsonx, and automation offerings. Infrastructure trends, particularly in distributed systems and storage, will remain important given recent order backlog growth.

Management highlighted actions to expand sales coverage, invest in specialized talent, and accelerate productivity through AI and automation. These initiatives are intended to support revenue acceleration and margin improvement over time.

Additional areas of focus include the impact of recent acquisitions, quantum computing investments, and overall client demand for AI-ready solutions as enterprises move from experimentation to scaled deployments.

Using AI Tools to Refine the Analysis

In reviewing results like these, I often find it helpful to run quick comparisons across peers and historical patterns. One tool I turn to for this is Tickeron’s AI Screener, an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. I find this approach keeps the focus on data rather than headlines alone.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: IBM

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


IBM's RSI Oscillator ascending out of oversold territory

The RSI Indicator for IBM moved out of oversold territory on July 24, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In of the 28 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 28, 2026. You may want to consider a long position or call options on IBM as a result. In of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for IBM just turned positive on July 31, 2026. Looking at past instances where IBM's MACD turned positive, the stock continued to rise in of 38 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IBM advanced for three days, in of 375 cases, the price rose further within the following month. The odds of a continued upward trend are .

IBM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

IBM moved below its 50-day moving average on July 14, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for IBM crossed bearishly below the 50-day moving average on July 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.382) is normal, around the industry mean (7.575). P/E Ratio (20.731) is within average values for comparable stocks, (71.761). IBM's Projected Growth (PEG Ratio) (2.376) is slightly higher than the industry average of (1.142). Dividend Yield (0.029) settles around the average of (0.025) among similar stocks. P/S Ratio (3.215) is also within normal values, averaging (146.029).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. IBM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are International Business Machines Corp (NYSE:IBM), Accenture PLC (NYSE:ACN), Unisys Corp (NYSE:UIS).

Industry description

The industry, whose total market cap runs into trillions, makes hardware/software that allows data to be stored, retrieved, transmitted, and manipulated on computers. With the ever-increasing relevance of data, the information technology (IT) industry has gained momentous growth over the years, and continues to thrive on innovation. Some of the behemoths in the industry are International Business Machines Corporation, Accenture, and VMware, Inc.

Market Cap

The average market capitalization across the Information Technology Services Industry is 9.18B. The market cap for tickers in the group ranges from 0 to 219.92B. IBM holds the highest valuation in this group at 219.92B. The lowest valued company is ARSC at 0.

High and low price notable news

The average weekly price growth across all stocks in the Information Technology Services Industry was 4%. For the same Industry, the average monthly price growth was 5%, and the average quarterly price growth was 51%. TASK experienced the highest price growth at 32%, while CYCU experienced the biggest fall at -58%.

Volume

The average weekly volume growth across all stocks in the Information Technology Services Industry was -68%. For the same stocks of the Industry, the average monthly volume growth was -16% and the average quarterly volume growth was -42%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 47
P/E Growth Rating: 64
Price Growth Rating: 58
SMR Rating: 72
Profit Risk Rating: 93
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
IBM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a manufacturer of various computer products through the use of advanced information technology

Industry InformationTechnologyServices

Profile
Details
Industry
Information Technology Services
Address
One New Orchard Road
Phone
+1 914 499-1900
Employees
305300
Web
http://www.ibm.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.